We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 105.00 | 36.21% | 395.00 | 390.00 | 400.00 | 405.00 | 305.00 | 305.00 | 147,631 | 16:28:47 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -12.72 | 482.33M |
TIDMMXCT
MaxCyte, Inc.
14 November 2019
MaxCyte to Present at 2019 Jefferies London Healthcare Conference
Gaithersburg, Maryland - 14 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, announces that President and Chief Executive Officer Doug Doerfler will present at the 2019 Jefferies London Healthcare Conference, to be held 20-21 November at the Waldorf Hilton Hotel.
The presentation will take place at 3:20 p.m. GMT on Thursday, 21 November, and will focus on MaxCyte's position at the forefront of the development of next generation cell-based medicines through its Life Sciences business and proprietary CARMA(TM) platform.
The presentation will be made available after the conference on the Investor section of MaxCyte's website.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six announced commercial licenses with aggregate potential milestones of more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer +1 301 944 1660 Financial PR Adviser Consilium Strategic Communications +44 (0)203 709 5700 Mary-Jane Elliott maxcyte@consilium-comms.com Chris Welsh Sukaina Virji
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRACKNDKFBDDNDD
(END) Dow Jones Newswires
November 14, 2019 02:01 ET (07:01 GMT)
1 Year Maxcyte Chart |
1 Month Maxcyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
